NasdaqGS - Delayed Quote • USD
NextCure, Inc. (NXTC)
At close: May 28 at 4:00 PM EDT
After hours: May 28 at 7:23 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.38 | -0.37 | -1.74 | -1.78 |
| Low Estimate | -0.41 | -0.42 | -1.86 | -2.03 |
| High Estimate | -0.34 | -0.32 | -1.62 | -1.49 |
| Year Ago EPS | -0.64 | -0.51 | -2.25 | -1.74 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.59 | -0.66 | -0.54 | -0.46 |
| EPS Actual | -0.64 | -0.51 | -0.52 | -0.61 |
| Difference | -0.05 | 0.15 | 0.02 | -0.15 |
| Surprise % | -8.50% | 22.70% | 3.70% | -32.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.38 | -0.37 | -1.74 | -1.78 |
| 7 Days Ago | -0.38 | -0.37 | -1.74 | -1.78 |
| 30 Days Ago | -0.41 | -0.39 | -1.67 | -1.68 |
| 60 Days Ago | -0.41 | -0.39 | -1.67 | -1.68 |
| 90 Days Ago | -0.61 | -0.64 | -2.54 | -1.76 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 2 | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NXTC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 40.60% | -- | -- | 7.90% |
| Next Qtr. | 27.50% | -- | -- | 10.20% |
| Current Year | 22.70% | -- | -- | 4.80% |
| Next Year | -2.30% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -31.70% | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/3/2024 |
| Reiterates | Needham: Buy to Buy | 5/3/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/22/2024 |
| Maintains | Needham: Buy to Buy | 3/20/2024 |
| Maintains | Needham: Buy to Buy | 12/14/2023 |
| Initiated | HC Wainwright & Co.: Buy | 8/8/2023 |
Related Tickers
ASMB Assembly Biosciences, Inc.
15.07
+0.53%
SPRO Spero Therapeutics, Inc.
1.4400
-2.04%
BOLT Bolt Biotherapeutics, Inc.
0.7608
-3.70%
TIL Instil Bio, Inc.
10.96
-0.63%
TBPH Theravance Biopharma, Inc.
8.41
+0.84%
ATXS Astria Therapeutics, Inc.
9.05
+0.33%
SYBX Synlogic, Inc.
1.6200
+1.25%
LVTX LAVA Therapeutics N.V.
2.3900
-8.43%
ACHL Achilles Therapeutics plc
0.9200
+1.10%
GLPG.AS Galapagos NV
25.14
-0.55%